KARDIGAN INC
KARD- EPS
- n/m
- Free cash flow
- n/m
Quarter to September 2026, against a year earlier
After hours trading: 11.54, unchanged, last trade Fri 4:01pm Eastern.
Follow KARD
Alert me
KARDIGAN INC (KARD) Return on invested capital
KARDIGAN INC's return on invested capital over the twelve months to Sep 30, 2026 was −187.2%, down 187.2 percentage points from fiscal 2025 (0.00%). That is below the Biotechnology industry median of 0.00% and below the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 0.00% | 0.00 |
| FY2024 | 0.00% | — |
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| INBX Inhibrx Biosciences, Inc. compare | 0.00% |
| GPCR Structure Therapeutics Inc. Sponsored ADR compare | 0.00% |
| SLN Silence Therapeutics PLC Sponsored ADR compare | 0.00% |
| MLYS Mineralys Therapeutics, Inc. compare | 0.00% |
| NKTR Nektar Therapeutics compare | −44.3% |
| KARD KARDIGAN INC | −187.2% |
| SVRA Savara Inc. compare | −1,161.6% |
| AAPG Ascentage Pharma Group International - Unsponsored ADR compare | — |
| VOR Vor Biopharma Inc. compare | — |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.06% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)